Your browser doesn't support javascript.
loading
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.
Evans, Jonathan P; Winiarski, Boleslaw K; Sutton, Paul A; Jones, Robert P; Ressel, Lorenzo; Duckworth, Carrie A; Pritchard, D Mark; Lin, Zhi-Xiu; Fretwell, Vicky L; Tweedle, Elizabeth M; Costello, Eithne; Goldring, Christopher E; Copple, Ian M; Park, B Kevin; Palmer, Daniel H; Kitteringham, Neil R.
Affiliation
  • Evans JP; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Winiarski BK; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Sutton PA; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Jones RP; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Ressel L; Department of Veterinary Pathology, Institute of Veterinary Science, University of Liverpool, Liverpool, United Kingdom.
  • Duckworth CA; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Pritchard DM; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Lin ZX; School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Fretwell VL; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Tweedle EM; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Costello E; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Goldring CE; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Copple IM; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Park BK; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Palmer DH; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Kitteringham NR; Clatterbridge Cancer Centre, Liverpool, United Kingdom.
Oncotarget ; 9(43): 27104-27116, 2018 06 05.
Article in En | MEDLINE | ID: mdl-29930754
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Oncotarget Year: 2018 Document type: Article Affiliation country: United kingdom Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Oncotarget Year: 2018 Document type: Article Affiliation country: United kingdom Country of publication: United States